Novartis Korea Venture Fund, OrbiMed Co-lead Series A Financing For South Korean mAb Developer PharmAbcine

SEOUL - Novartis Korea Venture Fund, OrbiMed's Caduceus Asia Partners and local vaccine producer Green Cross plan to invest $6 million in the next three years to support development of PharmAbcine's fully human monoclonal antibodies to treat cancer and inflammatory diseases